Xeris Biopharma Holdings, Inc., a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology and gastroenterology, announced a collaboration agreement with Merck, known as MSD outside of the United States and Canada, with an option to license Xeris’ suspension-based formulation technology, XeriJect™, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations.